Dexamethasone's uses in retinal diseases

Zeljka McBride, Sara P. Modjtahedi, Lawrence S Morse

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Steroids, having both anti-inflammatory and anti-angiogenic properties, are a useful therapeutic option in the treatment of retinal disease. Intravitreal steroids can be used in the treatment of various retinal conditions including diabetic and vasculo-occlusive macular edema, exudative macular degeneration, pseudophakic cystoid macular edema, and posterior uveitis. Although there are well known serious potential complications with intravitreal steroids, including glaucoma and endophthalmitis, recent studies have shown that intravitreal steroids may be used as a safe alternative to the practice of laser therapy for the treatment of macular edema secondary to diabetes or vein occlusions. Although there are several steroid formulations that may be used, this article focuses on the use of intravitreal dexamethasone. Dexamethasone is a potent anti-inflammatory agent that inhibits multiple inflammatory cytokines. Despite its established therapeutic benefit, side effects such as cataract formation and ocular hypertension/glaucoma raise concerns. Therefore, understanding the molecular and genetic effects of intraocular steroid treatments is of utmost importance and of clinical relevance. Our in vivo studies have elucidated several genes and pathways that are potentially altering the neuroprotective and/or neurodegenerative balance between glial and retinal ganglion cells during intravitreal steroid treatment, such as semaphorin signaling, a member of the neuronal axonal guidance signaling system. Furthermore, our more recent data results suggests that dexamethasone affects the balance of Th1, Th2 and Th17 cytokine production, which influences many pathological processes and plays both causative and protective roles in retinal disease.

Original languageEnglish (US)
Title of host publicationDexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects
PublisherNova Science Publishers, Inc.
Pages87-116
Number of pages30
ISBN (Print)9781628084054
StatePublished - 2013

Fingerprint

Retinal Diseases
Dexamethasone
Steroids
Macular Edema
Glaucoma
Therapeutics
Anti-Inflammatory Agents
Posterior Uveitis
Th1-Th2 Balance
Semaphorins
Ocular Hypertension
Endophthalmitis
Retinal Ganglion Cells
Macular Degeneration
Laser Therapy
Pathologic Processes
Neuroglia
Cataract
Molecular Biology
Veins

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

McBride, Z., Modjtahedi, S. P., & Morse, L. S. (2013). Dexamethasone's uses in retinal diseases. In Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects (pp. 87-116). Nova Science Publishers, Inc..

Dexamethasone's uses in retinal diseases. / McBride, Zeljka; Modjtahedi, Sara P.; Morse, Lawrence S.

Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects. Nova Science Publishers, Inc., 2013. p. 87-116.

Research output: Chapter in Book/Report/Conference proceedingChapter

McBride, Z, Modjtahedi, SP & Morse, LS 2013, Dexamethasone's uses in retinal diseases. in Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects. Nova Science Publishers, Inc., pp. 87-116.
McBride Z, Modjtahedi SP, Morse LS. Dexamethasone's uses in retinal diseases. In Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects. Nova Science Publishers, Inc. 2013. p. 87-116
McBride, Zeljka ; Modjtahedi, Sara P. ; Morse, Lawrence S. / Dexamethasone's uses in retinal diseases. Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects. Nova Science Publishers, Inc., 2013. pp. 87-116
@inbook{ee01e6619c934fda94f35a412887d1cd,
title = "Dexamethasone's uses in retinal diseases",
abstract = "Steroids, having both anti-inflammatory and anti-angiogenic properties, are a useful therapeutic option in the treatment of retinal disease. Intravitreal steroids can be used in the treatment of various retinal conditions including diabetic and vasculo-occlusive macular edema, exudative macular degeneration, pseudophakic cystoid macular edema, and posterior uveitis. Although there are well known serious potential complications with intravitreal steroids, including glaucoma and endophthalmitis, recent studies have shown that intravitreal steroids may be used as a safe alternative to the practice of laser therapy for the treatment of macular edema secondary to diabetes or vein occlusions. Although there are several steroid formulations that may be used, this article focuses on the use of intravitreal dexamethasone. Dexamethasone is a potent anti-inflammatory agent that inhibits multiple inflammatory cytokines. Despite its established therapeutic benefit, side effects such as cataract formation and ocular hypertension/glaucoma raise concerns. Therefore, understanding the molecular and genetic effects of intraocular steroid treatments is of utmost importance and of clinical relevance. Our in vivo studies have elucidated several genes and pathways that are potentially altering the neuroprotective and/or neurodegenerative balance between glial and retinal ganglion cells during intravitreal steroid treatment, such as semaphorin signaling, a member of the neuronal axonal guidance signaling system. Furthermore, our more recent data results suggests that dexamethasone affects the balance of Th1, Th2 and Th17 cytokine production, which influences many pathological processes and plays both causative and protective roles in retinal disease.",
author = "Zeljka McBride and Modjtahedi, {Sara P.} and Morse, {Lawrence S}",
year = "2013",
language = "English (US)",
isbn = "9781628084054",
pages = "87--116",
booktitle = "Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Dexamethasone's uses in retinal diseases

AU - McBride, Zeljka

AU - Modjtahedi, Sara P.

AU - Morse, Lawrence S

PY - 2013

Y1 - 2013

N2 - Steroids, having both anti-inflammatory and anti-angiogenic properties, are a useful therapeutic option in the treatment of retinal disease. Intravitreal steroids can be used in the treatment of various retinal conditions including diabetic and vasculo-occlusive macular edema, exudative macular degeneration, pseudophakic cystoid macular edema, and posterior uveitis. Although there are well known serious potential complications with intravitreal steroids, including glaucoma and endophthalmitis, recent studies have shown that intravitreal steroids may be used as a safe alternative to the practice of laser therapy for the treatment of macular edema secondary to diabetes or vein occlusions. Although there are several steroid formulations that may be used, this article focuses on the use of intravitreal dexamethasone. Dexamethasone is a potent anti-inflammatory agent that inhibits multiple inflammatory cytokines. Despite its established therapeutic benefit, side effects such as cataract formation and ocular hypertension/glaucoma raise concerns. Therefore, understanding the molecular and genetic effects of intraocular steroid treatments is of utmost importance and of clinical relevance. Our in vivo studies have elucidated several genes and pathways that are potentially altering the neuroprotective and/or neurodegenerative balance between glial and retinal ganglion cells during intravitreal steroid treatment, such as semaphorin signaling, a member of the neuronal axonal guidance signaling system. Furthermore, our more recent data results suggests that dexamethasone affects the balance of Th1, Th2 and Th17 cytokine production, which influences many pathological processes and plays both causative and protective roles in retinal disease.

AB - Steroids, having both anti-inflammatory and anti-angiogenic properties, are a useful therapeutic option in the treatment of retinal disease. Intravitreal steroids can be used in the treatment of various retinal conditions including diabetic and vasculo-occlusive macular edema, exudative macular degeneration, pseudophakic cystoid macular edema, and posterior uveitis. Although there are well known serious potential complications with intravitreal steroids, including glaucoma and endophthalmitis, recent studies have shown that intravitreal steroids may be used as a safe alternative to the practice of laser therapy for the treatment of macular edema secondary to diabetes or vein occlusions. Although there are several steroid formulations that may be used, this article focuses on the use of intravitreal dexamethasone. Dexamethasone is a potent anti-inflammatory agent that inhibits multiple inflammatory cytokines. Despite its established therapeutic benefit, side effects such as cataract formation and ocular hypertension/glaucoma raise concerns. Therefore, understanding the molecular and genetic effects of intraocular steroid treatments is of utmost importance and of clinical relevance. Our in vivo studies have elucidated several genes and pathways that are potentially altering the neuroprotective and/or neurodegenerative balance between glial and retinal ganglion cells during intravitreal steroid treatment, such as semaphorin signaling, a member of the neuronal axonal guidance signaling system. Furthermore, our more recent data results suggests that dexamethasone affects the balance of Th1, Th2 and Th17 cytokine production, which influences many pathological processes and plays both causative and protective roles in retinal disease.

UR - http://www.scopus.com/inward/record.url?scp=84892263015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892263015&partnerID=8YFLogxK

M3 - Chapter

SN - 9781628084054

SP - 87

EP - 116

BT - Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects

PB - Nova Science Publishers, Inc.

ER -